Recent Publications

A full list of publications can be found here.

  1. Ivens, E.; Cominetti, M. M. D.; Searcey M. Junctions in DNA: underexplored targets for therapeutic intervention. Bioorg. Med. Chem. 2022, 69, 116897.
  2. Bidula, S.; Nadzirin, I. B.; Cominetti, M. M. D.; Hickey, H.; Cullum, S. A.; Searcey, M.; Schimd, R.; Fountain, S. J. Structural basis of the negative allosteric modulation of 5-BDBD at human P2X4 receptors. Mol. Pharmacol. 2022, 101, 33-44.
  3. Nadzirin, I. B.;  Fortuny‐Gomez, A.; Ngum, N.; Richards, D.; Ali, S.; Searcey, M.; Fountain, S. J. Taspine is a natural product that suppresses P2X4 receptor activity via phosphoinositide 3‐kinase inhibition. Brit. J. Pharmacol. 2021, 178, 4859-4872.
  4. Ortuzar, N. ; Karu, K.; Presa, D.; Morais, G. R.; Sheldrake, H. M.; Shnyder, D. S.; Barnieh, F. M.; Loadman, P. M.; Patterson, L. H.; Pors, K.; Searcey, M. Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds. Bioorg. Med. Chem. 2021, 40, 116167.
  5. Cominetti, M. M. D.; Goddard, Z. R.; Howman, C. E.; O’Connell, M. A.; Searcey, M. Amino DSA analogues as payloads for antibody drug conjugates with multiple sites for conjugation. Initial studies and solid phase synthesis. Tetrahedron Lett 2021, 72, 15058.
  6. Goddard, Z. R.; Beekman, A. M.; Cominetti, M. M. D.; O’Connell, M. A.; Chambrier, I.; Cook, M. J.; Marin, M, J.; Russell, D. A.; Searcey, M. Peptide directed phthalocyanine-gold nanoparticles for selective photodynamic therapy of EGFR overexpressing cancers. RSC Med. Chem. 2021, 12, 288-292.
  7. Goddard, Z. R.; Marin, M. J.; Russell, D. A. Searcey, M. Active targeting of gold nanoparticles as cancer therapeutics. Chem. Soc. Rev.2020, 49, 8774-8789.
  8. Cartwright, O. C.; Beekman, A. M.; Cominetti, M.M.D.; Russell, D. A.; Searcey, M.  A peptide-duocarmycin conjugate targeting the Thomsen-Friedenreich antigen has potent and selective antitumour activity. Bioconjugate Chem.2020, 31, 1745-1749.
  9. Beekman, A. M.; Cominetti, M, M, D; Cartwright, O. C.; Boger, D. L.; Searcey, M. A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase. MedChemComm. 2019, 10, 2170-2174.
  10. Beekman, A. M.; Cominetti, M. D.; Walpole, S. J.; Prabhu, S.; O’Connell, M. A.; Angulo, J.; Searcey, M. Identification of selective protein-protein interaction inhibitors using efficient in silico peptide-directed ligand design. Chem. Sci 2019, 10, 4502-4508.
  11. Williams, M.; Bertrand, B.; Hughes, D. L.; Waller, Z. A. E.; Schmidt, C.; Ott, I.; O’Connell, M. A.; Searcey, M.; Bochmann, M. (C^ N pz^ C) Cyclometallated Au(III) dithiocarbamate complexes: synthesis, anticancer evaluation and mechanistic studies. Metallomics 2018, 10, 1655–1666.
  12. Williams, M.; Bertrand, B.; Fernandez-Cestau, J.; Waller, Z. A. E.; O’Connell, M. A.; Searcey, M.; Bochmann, M. (C^ N pz^ C) Au III complexes of acyclic carbene ligands: synthesis and anticancer properties Dalton Trans. 2018, 47, 13523-13534.
  13. Beekman, A. M.; Cominetti, M. D.; Searcey, M. Duocarmycins. Chapter 9 in Antibody Drug Conjugates Royal Society of Chemistry Publishing. 2018.
  14. Steel, R. J.; O’Connell, M. A.; Searcey, M. Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction Bioorg. Med. Chem. Lett. 2018, 28, 2728-2731 (Issue in honour of Dale Boger’s 65th birthday).
  15. Williams, M.; Green, A. I.; Fernandez-Cestau, J.; Hughes, D. L.; O’Connell, M. A.; Searcey, M.; Bertrand, B.; Bochmann, M. (C^ N pz^ C) Au III complexes of acyclic carbene ligands: synthesis and anticancer properties Dalton Trans. 2017, 46, 13397-13408.
  16. Benoit, B.; Fernandez-Cestau, J.; Angulo, J.; Cominetti, M.; Waller, Z. A. E.; Searcey, M.; O’Connell, M. A; Bochmann, M. Cytotoxicity of Pyrazine-Based Cyclometalated (C^ Npz^ C) Au (III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties Inorg. Chem. 2017, 56, 5728-5740.
  17. Austin, M. J.; Hearnshaw, S. J.; Mitchenall, L. A.; McDermott, P. J.; Howell, L. A.; Maxwell. A.; Searcey M. A natural product inspired fragment based approach towards the development of novel anti-bacterial agents. MedChemComm 2016, 7, 1387-1391
  18. Angulo, J.; Goffin, S. A.; Gandhi, D.; Searcey, M.; Howell, L. A. STD NMR initial growth rates approach in protein-protein interactions: Unveiling the “three finger pharmacophore” required for p53-MDM2 inhibition by Saturation-Transfer Difference (STD) NMR Initial Growth-Rates Approach. Chem. Eur. J. 2016, 22, 5858-5862.
  19. Stephenson, M. J.; Howell, L. A.; O’Connell, M. A.; Fox, K. R.; Adcock, C.; Kingston, J.; Sheldrake, H.; Pors, K.; Collingwood, S. P.; Searcey, M. Solid-Phase Synthesis of Duocarmycin Analogues and the Effect of C-Terminal Substitution on Biological Activity. J. Org. Chem. 2015, 19, 9454-9467.
  20. Cominetti, M.; Goffin, S. A.; Raffel, E.; Turner, K. D.; Ramoutar, J. C.; O’Connell, M. A.; Howell, L. A.; Searcey, M. Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin. Bioorg. Med. Chem. Lett. 2015, 25, 4878-4880.
  21. Vinader, V.; Sadiq, M.; Sutherland, M.; Huang, M.: Loadman, P. M.; Elsalem, L.; Shnyder, S. D.; Cui, H.; Afarinkia, K.; Searcey, M.; Patterson, L. H. ; Pors, K. Probing cytochrome P450-mediated activation with a truncated azinomycin analogue Med. Chem. Commun. 2015, 6, 187-191.